Yukmijihwang-Tang Suppresses Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)-Induced Osteoclast Differentiation and Prevents Ovariectomy (OVX)-Mediated Bone Loss
Open Access
- 14 December 2021
- Vol. 26 (24) , 7579
Abstract
Yukmijihwang-tang (YJ) has been used to treat diabetes mellitus, renal disorders, and cognitive impairment in traditional medicine. This study aimed to evaluate the anti-osteoporotic effect of YJ on ovariectomy (OVX)-induced bone loss in a rat and receptor activator of nuclear factor kappa-B ligand (RANKL)-mediated osteoclast differentiation in bone marrow macrophages (BMMs). YJ reduced the formation of tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cells (MNCs) in an osteoclast/osteoblast co-culture system by regulating the ratio of RANKL/osteoprotegerin (OPG) by osteoblasts. Overall, YJ reduced TRAP-positive cell formation and TRAP activity and F-actin ring formation. Analysis of the underlying mechanisms indicated that YJ inhibited the activation of the nuclear factor of activated T cell cytoplasmic 1 (NFATc1) and c-Fos, resulting in the suppression of osteoclast differentiation-related genes such as TRAP, ATPase, H+ transporting, lysosomal 38 kDa, V0 subunit d2, osteoclast-associated receptor, osteoclast-stimulatory transmembrane protein, dendritic cell-specific transmembrane protein, matrix metalloproteinase-9, cathepsin K, and calcitonin receptor. YJ also inhibited the nuclear translocation of NFATc1. Additionally, YJ markedly inhibited RANKL-induced phosphorylation of signaling pathways activated in the early stages of osteoclast differentiation including the p38, JNK, ERK, and NF-κB. Consistent with these in vitro results, the YJ-administered group showed considerably attenuated bone loss in the OVX-mediated rat model. These results provide promising evidence for the potential novel therapeutic application of YJ for bone diseases such as osteoporosis.Keywords
Funding Information
- National Research Foundation of Korea (NRF-2019R1C1C1002761)
This publication has 37 references indexed in Scilit:
- An n-of-1 Trial Service in Clinical Practice: Testing the Effectiveness of Liuwei Dihuang Decoction for Kidney-Yin Deficiency SyndromeEvidence-Based Complementary and Alternative Medicine, 2013
- Liuwei Dihuang Lowers Body Weight and Improves Insulin and Leptin Sensitivity in Obese RatsEvidence-Based Complementary and Alternative Medicine, 2011
- OSCAR is a collagen receptor that costimulates osteoclastogenesis in DAP12-deficient humans and miceJournal of Clinical Investigation, 2011
- Disorders of Bone RemodelingAnnual Review of Pathology: Mechanisms of Disease, 2011
- Safety Evaluation of Yukmijihwang-tang: Assessment of Acute and Subchronic Toxicity in RatsEvidence-Based Complementary and Alternative Medicine, 2010
- Anin vitrostudy of the antioxidant activities and effect on human DNA of the Chinese herbal decoction ‘Liu Wei Di Huang’International Journal of Food Sciences and Nutrition, 2009
- NFATc1 Induces Osteoclast Fusion Via Up-Regulation of Atp6v0d2 and the Dendritic Cell-Specific Transmembrane Protein (DC-STAMP)Molecular Endocrinology, 2008
- M‐CSF, c‐Fms, and Signaling in Osteoclasts and their PrecursorsAnnals of the New York Academy of Sciences, 2006
- Risk Factors for Longitudinal Bone Loss in Elderly Men and Women: The Framingham Osteoporosis StudyJournal of Bone and Mineral Research, 2000
- Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and ActivationCell, 1998